达成的喷射分数和达帕格利弗洛辛在心力衰竭中的作用
Sara R O Siqueira1, Maria A Pabon1, Muthiah Vaduganathan1
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
JACC. Heart failure
|August 20, 2025
概括
达帕格利弗洛辛有效治疗心力衰竭与改善的喷射分数 (HFimpEF),无论喷射分数的改善. 患有HFimpEF的患者,即使LVEF≥60%,也面临残留风险,并从达帕格利弗洛辛中受益.
科学领域:
- 心脏病学
- 药理学
背景情况:
- 没有研究过心力衰竭患者的射分数 (HFimpEF).
- 这些患者面临的残留风险与持续高LVEF患者相似.
- 改善LVEF对预后和治疗的影响尚不清楚.
研究的目的:
- 调查 LVEF 的改善程度是否会影响 HFimpEF 的预后.
- 确定LVEF的改善是否会改变达帕格利弗洛辛在HFimpEF中的治疗效果.
主要方法:
- 对DELIVER试验HFimpEF子集的分析.
- 检查基线LVEF与主要结局 (高频恶化或心血管死亡) 之间的关联.
- 评估LVEF的改善是否会改变达帕格利弗洛辛的治疗反应.
主要成果:
- 在1,151名患者中,HFimpEF的基线LVEF水平有所不同.
- 在所有LVEF组中,达帕格利弗洛辛始终降低了主要结局风险.
- 没有显著的LVEF改善和达帕格利弗洛辛疗效之间的相互作用 (P=0. 19).
结论:
- 在HFimpEF患者中,无论LVEF的改善程度如何,达帕格利弗洛辛的疗效和安全性都是一致的.
- 达到≥60%的LVEF患者仍然面临显著的临床事件风险.
- 达帕格利弗洛辛对HFimpEF患者提供了一致的益处.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434


